Women with ATM, CHEK2, or PALB2 mutations may benefit from starting annual breast cancer screening with MRI between the ages and 30 to 35 and an annual MRI and mammogram starting at age 40.
Women at high risk for breast cancer who had genetic testing benefited psychologically from knowing the results of the test.
Research shows that women with an abnormal BRCA1 or BRCA2 gene who've been diagnosed with breast cancer have a higher risk of being diagnosed with a new, different cancer in the opposite breast compared to women without an abnormal BRCA1 or BRCA2 gene.
Research suggests that just as many younger women with an abnormal BRCA1 gene who develop breast cancer are alive 10 years after diagnosis as younger women without an abnormal BRCA1 gene who develop breast cancer.
The results from panel genetic tests looking at a dozen or more genes can be more complex, but these results are not causing women diagnosed with breast cancer more worry than older tests looking at only one or two genes.
A study suggests that genetic test results are not being clearly communicated to women and may be causing them to opt for breast cancer treatment that is more aggressive than they need.
People diagnosed with metastatic HER2-negative breast cancer with a BRCA1 or BRCA2 mutation treated with experimental veliparib and chemotherapy lived about 2 months longer without the cancer growing if they continued on veliparib after stopping chemotherapy.
Women with a BRCA1 or BRCA2 mutation who become pregnant after being treated for breast cancer don't have a higher risk of recurrence and their babies are healthy.
A study strongly suggests that women with a BRCA1 mutation have a slightly higher risk of an uncommon but aggressive type of uterine cancer.
On Jan. 12, 2018, the FDA approved Lynparza to treat metastatic HER2-negative breast cancer in women with a BRCA1 or BRCA2 mutation.
A new study suggests that having an abnormal BRCA2 gene has a better prognosis 5 years after diagnosis than having an abnormal BRCA1 gene.
A study suggests that a woman's risk of breast and ovarian cancer may vary depending on the type of mutation a woman has and where the mutation is located on the BRCA1 or BRCA2 gene.
A study suggests that breast cancer screening with MRI twice per year is better than one mammogram per year for finding breast cancer early in young women with a high risk of breast cancer.
A study found that women with a BRCA1 mutation had levels of a hormone that indicates how many eggs are left in the ovaries that were 25% lower than women who didn't have the mutation.
The results of¬†a new¬†study are particularly important for women with a family member who has an abnormal BRCA1 or BRCA2 gene. Even though the women in the study tested negative for an abnormal BRCA1 or...
New research suggests that parents should wait until their children reach early adulthood before talking to them about abnormal genetic test results.
Experimental targeted therapy medicines -- called PARP inhibitors -- may make chemotherapy work better against aggressive forms of breast cancer and also may be able to treat breast cancer alone, without chemotherapy.
Research suggests that women with an abnormal BRCA1 or BRCA2 gene who have been diagnosed with breast cancer are 4 times more likely to be diagnosed with a new cancer in the opposite breast compared to women without an abnormal breast cancer gene diagnosed with breast cancer.
A study suggests women with an abnormal BRCA1 gene have worse breast cancer survival and recurrence rates than women with an abnormal BRCA2 gene or women who don't have either abnormal gene.
A study found that more than 25% of people with an abnormal BRCA1 or BRCA2 gene being treated for advanced-stage breast, ovarian, pancreatic, or prostate cancer got some benefit from olaparib, an experimental targeted therapy medicine.
Women with an abnormal BRCA1 gene diagnosed with breast cancer are more likely to survive if they have their ovaries removed.
The targeted therapy talazoparib resulted in longer progression-free survival compared to chemotherapy in women with a BRCA1 or BRCA2 mutation diagnosed with metastatic HER2-negative breast cancer.
A study suggests that environmental and lifestyle factors are causing women with a BRCA1 or BRCA2 mutation to be diagnosed with breast and/or ovarian cancer at younger ages.
Women diagnosed with advanced-stage, triple-negative breast cancer who have a BRCA1 or BRCA2 mutation have a better response to carboplatin than Taxotere.